{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"451"},{"groupId":"OG001","value":"214"}]}],"title":"Participants with TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"88"}]}],"title":"Participants with Serious TEAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"230"}],"units":"Participants"}],"description":"An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE was considered a TEAE if the onset date was on or after the start of study treatment or if the onset date was missing, or if the AE had an onset date before the start of study treatment but worsened in severity after the study treatment until 30 days after the last dose of study treatment or a new treatment of anti-tumor therapy, whichever was earlier. After this period, treatment-related SAEs were also considered as TEAEs. AEs with an unknown/not reported onset date were also included.","groups":[{"description":"Participants received 5 mg of fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG000","title":"Fruquintinib + BSC Group"},{"description":"Participants received placebo matched to fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG001","title":"Placebo + BSC Group"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"SP included all randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From start of study drug administration up to approximately 40 months","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs","type":"SECONDARY","unitOfMeasure":"Participants"}